



Novel Anticancer Drug Delivery Systems

Guest Editors:

Prof. Dr. Sanjay Garg

School of Pharmacy and Medical
Sciences, University of South
Australia, Adelaide, SA 5000,
Australia

Dr. Usha Y. Nayak

Department of Pharmaceutics,
Manipal College of
Pharmaceutical Sciences
(MCOPS), Manipal University,
Manipal, Karnataka 576104, India

Deadline for manuscript
submissions:

closed (31 October 2019)

Message from the Guest Editors

Currently, the cancer treatment strategies include surgery, chemotherapy, and radiotherapy, and it is widely known that these therapies inhibit the growth also of normal cells and are associated with high toxicity. The area of cancer therapy is a highly dynamic field, and breakthrough advancements are being made to develop novel strategies. Several strategies, such as receptor-based targeting, intracellular drug targeting, stimuli-based drug release, magnetic drug targeting, ultrasound-mediated drug delivery, gene delivery, and cancer stem cell therapy, have added new dimensions to the treatment approaches. These strategies aid in the selective detection and killing of tumour cells with minimal side effects and may be useful to reduce the chances of multidrug resistance, thus improving the quality of life of patients.

This Special Issue focuses on "Novel Anticancer Drug Delivery Systems" which could help solve issues related to side effects, high toxicities, and drug resistance of anticancer drugs. Articles concerning all aspects of novel anticancer drug delivery systems, especially, new materials, strategies, and synthetic approaches are welcome for this Special Issue.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma